Pexep: Advanced Relief for Major Depressive Disorder
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.58 | $52.21 (0%) | 🛒 Add to cart |
| 120 | $0.55 | $69.62 $66.27 (5%) | 🛒 Add to cart |
| 180 | $0.51 | $104.42 $92.37 (12%) | 🛒 Add to cart |
| 270 | $0.48 | $156.64 $130.53 (17%) | 🛒 Add to cart |
| 360 | $0.43
Best per pill | $208.85 $155.63 (25%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.70 | $42.17 (0%) | 🛒 Add to cart |
| 90 | $0.66 | $63.26 $59.24 (6%) | 🛒 Add to cart |
| 120 | $0.60 | $84.34 $72.29 (14%) | 🛒 Add to cart |
| 180 | $0.55 | $126.51 $99.40 (21%) | 🛒 Add to cart |
| 270 | $0.50 | $189.77 $135.55 (29%) | 🛒 Add to cart |
| 360 | $0.45
Best per pill | $253.03 $162.66 (36%) | 🛒 Add to cart |
Synonyms | |||
Pexep represents a significant advancement in the pharmacological management of Major Depressive Disorder (MDD). As a selective serotonin reuptake inhibitor (SSRI) containing the active ingredient escitalopram oxalate, it is engineered to restore neurotransmitter balance with precision. Clinically validated for its efficacy and favorable tolerability profile, Pexep offers healthcare providers a trusted option for initiating and maintaining antidepressant therapy. Its mechanism targets the core pathophysiology of depression, providing patients with a pathway toward sustained emotional stability and improved daily functioning.
Features
- Contains escitalopram oxalate 10mg or 20mg per tablet
- Selective serotonin reuptake inhibitor (SSRI) class
- Bioequivalent to reference listed drug
- Film-coated for ease of swallowing
- Manufactured under cGMP conditions
- Available in 30- and 90-count bottles with child-resistant caps
- Stability assured for 24 months under recommended storage conditions
Benefits
- Promotes restoration of serotonin balance in the central nervous system
- Reduces core symptoms of depression, including low mood and anhedonia
- Demonstrates a lower side effect burden compared to older antidepressants
- Supports improved social and occupational functioning over time
- May alleviate associated anxiety symptoms often present in depressive disorders
- Provides a predictable pharmacokinetic profile for consistent dosing
Common use
Pexep is indicated for the acute and maintenance treatment of Major Depressive Disorder in adults. It is also widely used off-label under clinical supervision for generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and obsessive-compulsive disorder (OCD). Treatment is typically initiated after a thorough diagnostic assessment confirms the presence of a serotonin-related mood or anxiety disorder. Many clinicians consider it a first-line option due to its established efficacy and generally manageable side effect profile.
Dosage and direction
The recommended starting dosage for most adults is 10 mg once daily, with or without food. After a minimum of one week, the dose may be increased to 20 mg daily based on therapeutic response and tolerability. Dosage adjustments should be made under strict medical supervision, particularly in special populations such as the elderly or those with hepatic impairment, where a maximum dose of 10 mg daily is often advised. Tablets should be swallowed whole with water and not crushed or chewed. Consistent daily administration is critical to maintaining stable plasma concentrations.
Precautions
Patients should be monitored closely for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial months of therapy or after dosage changes. Pexep may impair judgment, thinking, or motor skills; patients should exercise caution when operating machinery or driving until they understand how the medication affects them. Use with caution in patients with a history of mania/hypomania, seizures, or bleeding disorders. Serotonin syndrome, though rare, requires immediate medical attention if symptoms such as agitation, hallucinations, or tachycardia occur.
Contraindications
Pexep is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy due to the risk of serious, sometimes fatal, drug interactions. It is also contraindicated in individuals with known hypersensitivity to escitalopram, citalopram, or any inactive ingredients in the formulation. Patients with congenital long QT syndrome or those taking drugs that prolong the QT interval should avoid Pexep unless the potential benefits outweigh the risks under careful cardiologic supervision.
Possible side effects
Common adverse reactions (≥5% incidence) include nausea, insomnia, fatigue, somnolence, increased sweating, and ejaculation disorder. Less frequently, patients may experience dry mouth, dizziness, constipation, decreased libido, or anxiety. Most side effects are mild to moderate and often subside within the first two weeks of treatment. Serious but rare side effects include serotonin syndrome, abnormal bleeding, hyponatremia (especially in elderly patients), angle-closure glaucoma, and QT interval prolongation at higher doses.
Drug interaction
Pexep is metabolized primarily by CYP2C19 and CYP3A4 enzymes. Concomitant use with strong inhibitors of these enzymes (e.g., fluconazole, fluvoxamine) may increase escitalopram plasma concentrations. Conversely, inducers like carbamazepine may reduce efficacy. Avoid concomitant use with other serotonergic drugs (tramadol, triptans, other SSRIs/SNRIs) due to additive serotonergic effects. NSAIDs, aspirin, or warfarin may increase bleeding risk. Use with drugs that prolong QT interval (e.g., antipsychotics, antiarrhythmics) requires careful monitoring.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose to make up for a missed one is not recommended, as it may increase the risk of side effects. Patients should be advised to maintain a consistent daily routine or use pill organizers to support adherence.
Overdose
Symptoms of overdose may include dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In severe cases, seizures, coma, or ECG changes (including QT prolongation) may occur. There is no specific antidote; management consists of supportive care and symptomatic treatment. Gastric lavage or activated charcoal may be considered if ingestion was recent. ECG monitoring is advised for at least 24 hours in symptomatic patients.
Storage
Store at room temperature (20°–25°C or 68°–77°F), with excursions permitted between 15°–30°C (59°–86°F). Keep the bottle tightly closed in its original packaging to protect from light and moisture. Do not store in bathrooms or other damp areas. Keep out of reach of children and pets. Dispose of unused or expired medication through a medicine take-back program or according to FDA-recommended disposal guidelines.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or discontinuing any medication. Individual patient responses may vary based on health status, genetics, and concomitant conditions. The prescribing physician should be the primary source of guidance regarding the use of Pexep.
Reviews
Clinical studies and post-marketing surveillance consistently report significant improvement in depressive symptoms for a majority of patients treated with escitalopram. In randomized controlled trials, nearly 60–70% of patients achieved response (≥50% reduction in depression rating scales), with remission rates approximating 30–40% after 8 weeks of treatment. Patient-reported outcomes often highlight improved mood, energy, and overall quality of life. Long-term data support its efficacy in relapse prevention, with many patients maintaining stability on continued therapy.